SYED RIZVI: Open Payments
NPI 1396824363 · MANASSAS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,309 in 69 payments from 15 companies in 2025. Trend: 2023 $1,413 · 2024 $1,788 · 2025 $1,309
Food & beverage: $1,309
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $187 |
| ABBVIE INC. | 13 | $185 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Vanda Pharmaceuticals Inc. | 5 | $131 |
| Axsome Therapeutics, Inc. | 5 | $113 |
| Lundbeck LLC | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Neurocrine BioSciences, Inc. | 4 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $69 |
| Corium, LLC | 4 | $64 |
Products named: ARISTADA, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, Auvelity, FANAPT, CAPLYTA, INGREZZA.
Industry payments across VA — which companies pay providers there.
